Skip to content
AnalystLens

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Mar 18, 2024)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed March 18, 2024
Period End
March 18, 2024
Securities
BMYCELG-RIBMYMP
In the record · 2016–202610-K1110-Q328-K169

BMY filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 169 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Nov ’19Nov ’19
  2. Leadership change8-K · Aug ’21Aug ’21
  3. Leadership change8-K · Jul ’25Jul ’25

01—Abstract

Summary

Summary of the 8-K filed March 18, 2024. Cited figures are marked; the original filing is the authoritative source.

On March 18, 2024, Bristol-Myers Squibb (BMS) completed its acquisition of Karuna Therapeutics, and Karuna is now a wholly owned subsidiary.

Each outstanding share of Karuna common stock (excluding certain excluded shares) was converted into the right to receive $330.00a in cash, without interest and subject to required withholding taxes. Karuna's shares have stopped trading on the Nasdaq Global Select Market. The main asset is KarXT (xanomeline-trospium), an antipsychotic with a novel mechanism of action for schizophrenia, which has a PDUFA date of September 26, 2024.

It is also in registrational trials for adjunctive schizophrenia therapy and for psychosis in Alzheimer's disease, with potential expansion to bipolar I disorder and Alzheimer's disease agitation. BMS also gained Karuna's early-stage and preclinical pipeline. The financial impact is front-loaded and largely non-recurring.

The transaction is accounted for as an asset acquisition, which produces an approximately $12 billionb one-time, non-deductible Acquired In-Process Research and Development (IPR&D) charge. This charge reduces both GAAP and non-GAAP EPS by about $5.93 in the first quarter of 2024 and for full-year 2024. Separately, BMS expects the deal to dilute non-GAAP diluted EPS by about $0.30 in 2024, driven mainly by financing costs from a recently completed debt issuance.

BMS plans to offset operating costs through resource allocation, cost efficiencies and portfolio prioritization, and says it will maintain its investment-grade credit ratings, continue business development, and keep paying dividends and repurchasing shares. Investors should read the transaction alongside BMS's February 2, 2024 outlook.

BMS will update its financial outlook when it reports first-quarter 2024 results on April 25, 2024. The filing's forward-looking statements highlight risks, including whether KarXT's commercial potential and expected synergies are realized, possible legal proceedings related to the merger agreement, and employee retention.

02—Key points

Key Highlights

  1. BMS completed its acquisition of Karuna Therapeutics on March 18, 2024; Karuna is now a wholly owned subsidiary and its shares no longer trade on Nasdaq.
  2. Karuna shareholders receive $330.00 per share in cash, without interest and subject to required withholding taxes.
  3. The lead asset, KarXT (xanomeline-trospium), has a PDUFA date of September 26, 2024 for adult schizophrenia, with additional registrational trials in adjunctive schizophrenia and Alzheimer's disease psychosis.
  4. Accounting as an asset acquisition creates an approximately $12 billion one-time, non-deductible Acquired IPR&D charge, reducing GAAP and non-GAAP EPS by about $5.93 in Q1 2024 and for full-year 2024.
  5. The deal is expected to dilute 2024 non-GAAP diluted EPS by about $0.30, mainly from financing costs of a recent debt issuance.
  6. BMS plans to offset transaction operating expenses through cost efficiencies and portfolio prioritization while maintaining investment-grade ratings and shareholder returns.
  7. BMS will update its financial outlook with Q1 2024 results on April 25, 2024.

03—Questions

Frequently Asked Questions

  1. How much will shareholders of Karuna receive for each share?

    Each share of Karuna common stock outstanding immediately before the merger's effective time (excluding certain excluded shares) was converted into the right to receive $330.00 in cash, without interest and subject to any required withholding taxes.

  2. What is the main value driver of the acquisition?

    The primary asset is KarXT (xanomeline-trospium), an antipsychotic with a novel mechanism of action. It has a PDUFA date of September 26, 2024 for adult schizophrenia and is in registrational trials for adjunctive schizophrenia therapy and psychosis in Alzheimer's disease, with potential expansion to bipolar I disorder and Alzheimer's disease agitation. The company also acquired Karuna's early-stage and preclinical pipeline.

  3. How will the acquisition affect BMS's 2024 earnings?

    BMS expects a one-time, non-deductible Acquired IPR&D charge of about $12 billion, which reduces GAAP and non-GAAP EPS by about $5.93 in Q1 2024 and for full-year 2024. Separately, the deal is expected to dilute 2024 non-GAAP diluted EPS by about $0.30, mainly from debt financing costs.

  4. Does the acquisition change BMS's commitment to shareholders or credit ratings?

    No. BMS states that its cash flows and financial profile support continued commitment to strong investment-grade credit ratings, continued business development, and ongoing dividends and share repurchases. It also plans to offset transaction operating expenses through resource allocation, cost efficiencies and portfolio prioritization.

  5. When will investors get an updated financial outlook?

    BMS will provide an updated financial outlook when it reports first-quarter 2024 results on April 25, 2024. Investors should consider the impacts described in this filing alongside the outlook issued on February 2, 2024.

04—Continue

← View all 8-K filings